Management of chronic myeloid leukemia in 2023–common ground and common sense
J Senapati, K Sasaki, GC Issa, JH Lipton… - Blood cancer …, 2023 - nature.com
With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2018 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology
MW Deininger, NP Shah, JK Altman, E Berman… - Journal of the National …, 2020 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …
Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial
Purpose We report the 5-year analysis from the phase III Dasatinib Versus Imatinib Study in
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …
Treatment-Naïve Chronic Myeloid Leukemia Patients (DASISION) trial, evaluating long-term …
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Abstract In the phase 3 Evaluating Nilotinib Efficacy and Safety in Clinical Trials–Newly
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Diagnosed Patients (ENESTnd) study, nilotinib resulted in earlier and higher response rates …
Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions
AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
AA Wylie, J Schoepfer, W Jahnke, SW Cowan-Jacob… - Nature, 2017 - nature.com
Chronic myeloid leukaemia (CML) is driven by the activity of the BCR–ABL1 fusion
oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with …
oncoprotein. ABL1 kinase inhibitors have improved the clinical outcomes for patients with …
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti… - Blood, The Journal …, 2013 - ashpublications.org
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …
inhibitors, mandate regular updating of concepts and management. A European …
Chronic myeloid leukemia, version 1.2019, NCCN clinical practice guidelines in oncology
JP Radich, M Deininger, CN Abboud, JK Altman… - Journal of the National …, 2018 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
(Ph), resulting from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] that …
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
E Jabbour, H Kantarjian - American journal of hematology, 2020 - Wiley Online Library
Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …